BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 11176565)

  • 21. HIV infection/acquired immunodeficiency syndrome at Siriraj Hospital, 2002: time for secondary prevention.
    Anekthananon T; Ratanasuwan W; Techasathit W; Rongrungruang Y; Suwanagool S
    J Med Assoc Thai; 2004 Feb; 87(2):173-9. PubMed ID: 15061301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy.
    Soriano V; Dona C; Rodríguez-Rosado R; Barreiro P; González-Lahoz J
    AIDS; 2000 Mar; 14(4):383-6. PubMed ID: 10770540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV infection and AIDS.
    Lloyd A
    P N G Med J; 1996 Sep; 39(3):174-80. PubMed ID: 9795558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study.
    Podlekareva D; Mocroft A; Dragsted UB; Ledergerber B; Beniowski M; Lazzarin A; Weber J; Clumeck N; Vetter N; Phillips A; Lundgren JD;
    J Infect Dis; 2006 Sep; 194(5):633-41. PubMed ID: 16897662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteonecrosis of the hip (Legg-Calvé-Perthes disease) in human immunodeficiency virus-infected children.
    Gaughan DM; Mofenson LM; Hughes MD; Seage GR; Ciupak GL; Oleske JM;
    Pediatrics; 2002 May; 109(5):E74-4. PubMed ID: 11986480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.
    Kirk O; Reiss P; Uberti-Foppa C; Bickel M; Gerstoft J; Pradier C; Wit FW; Ledergerber B; Lundgren JD; Furrer H;
    Ann Intern Med; 2002 Aug; 137(4):239-50. PubMed ID: 12186514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opportunistic infections: an update.
    Furrer H; Fux C
    J HIV Ther; 2002 Feb; 7(1):2-7. PubMed ID: 11956497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010.
    Buchacz K; Lau B; Jing Y; Bosch R; Abraham AG; Gill MJ; Silverberg MJ; Goedert JJ; Sterling TR; Althoff KN; Martin JN; Burkholder G; Gandhi N; Samji H; Patel P; Rachlis A; Thorne JE; Napravnik S; Henry K; Mayor A; Gebo K; Gange SJ; Moore RD; Brooks JT;
    J Infect Dis; 2016 Sep; 214(6):862-72. PubMed ID: 27559122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current scenario of opportunistic and co-infections in HIV-infected individuals at a tertiary care hospital in Mumbai, India.
    Chavan VR; Chaudhary V; Ahir P; Mehta R; Mavani PS; Kerkar C; Pramanik JM
    Indian J Med Microbiol; 2015; 33(1):78-83. PubMed ID: 25560006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts.
    Yazdanpanah Y; Chêne G; Losina E; Goldie SJ; Merchadou LD; Alfandari S; Seage GR; Sullivan L; Marimoutou C; Paltiel AD; Salamon R; Mouton Y; Freedberg KA
    Int J Epidemiol; 2001 Aug; 30(4):864-71. PubMed ID: 11511618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opportunistic Illnesses in Children With HIV Infection in the United States, 1997-2016.
    Nesheim SR; Balaji A; Hu X; Lampe M; Dominguez KL
    Pediatr Infect Dis J; 2021 Jul; 40(7):645-648. PubMed ID: 34014622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in the clinical spectrum of opportunistic illnesses in persons with HIV infection in Taiwan in the era of highly active antiretroviral therapy.
    Sun HY; Chen MY; Hsieh SM; Sheng WH; Chang SY; Hsiao CF; Hung CC; Chang SC
    Jpn J Infect Dis; 2006 Oct; 59(5):311-6. PubMed ID: 17060697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opportunistic and other infections in HIV-infected children in Latin America compared to a similar cohort in the United States.
    Alarcón JO; Freimanis-Hance L; Krauss M; Reyes MF; Cardoso CA; Mussi-Pinhata MM; Cardoso E; Hazra R;
    AIDS Res Hum Retroviruses; 2012 Mar; 28(3):282-8. PubMed ID: 21902581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.
    Jacobson MA; French M
    AIDS; 1998; 12 Suppl A():S157-63. PubMed ID: 9632998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world.
    Kaplan JE; Hu DJ; Holmes KK; Jaffe HW; Masur H; De Cock KM
    Am J Trop Med Hyg; 1996 Jul; 55(1):1-11. PubMed ID: 8702012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.